Panadol Coffein 500 mg / 65 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

panadol coffein 500 mg / 65 mg tabletti, kalvopäällysteinen

haleon denmark aps - caffeine, paracetamol - tabletti, kalvopäällysteinen - 500 mg / 65 mg - parasetamoli

DARUNAVIR SANDOZ 75 mg tabletti, kalvopäällysteinen Suomi - suomi - Fimea (Suomen lääkevirasto)

darunavir sandoz 75 mg tabletti, kalvopäällysteinen

sandoz a/s sandoz a/s - darunavirum - tabletti, kalvopäällysteinen - 75 mg - darunaviiri

Anagrelide ratiopharm 0.5 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

anagrelide ratiopharm 0.5 mg kapseli, kova

teva b.v. - anagrelide hydrochloride monohydrate - kapseli, kova - 0.5 mg - anagrelidi

ANAGRELIDE RATIOPHARM 1 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

anagrelide ratiopharm 1 mg kapseli, kova

teva b.v. - anagrelidi hydrochloridum monohydricum - kapseli, kova - 1 mg - anagrelidi

Fasenra Euroopan unioni - suomi - EMA (European Medicines Agency)

fasenra

astrazeneca ab - benralizumab - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - fasenra on merkitty add huolto hoito aikuisilla potilailla, joilla on vaikea eosinofiilinen astma on riittävästi hallinnassa huolimatta korkea-annos inhaloitavat kortikosteroidit plus pitkävaikutteista β-agonistit.

Ultomiris Euroopan unioni - suomi - EMA (European Medicines Agency)

ultomiris

alexion europe sas - ravulizumab - hemoglobinuria, paroxysmal - selektiiviset immunosuppressantit - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Anagrelid Orion 0.5 mg kapseli, kova Suomi - suomi - Fimea (Suomen lääkevirasto)

anagrelid orion 0.5 mg kapseli, kova

orion corporation - anagrelide hydrochloride monohydrate - kapseli, kova - 0.5 mg - anagrelidi

Treposa 10 mg/ml infuusioneste, liuos Suomi - suomi - Fimea (Suomen lääkevirasto)

treposa 10 mg/ml infuusioneste, liuos

amomed pharma gmbh - treprostinil sodium - infuusioneste, liuos - 10 mg/ml - treprostiniili

Quofenix Euroopan unioni - suomi - EMA (European Medicines Agency)

quofenix

a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumiini - yhteisön hankkimat infektiot - systeemiset bakteerilääkkeet, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4. 4 ja 5. on otettava huomioon viralliset ohjeet antibioottien tarkoituksenmukaisesta käytöstä.

Zelnorm Euroopan unioni - suomi - EMA (European Medicines Agency)

zelnorm

novartis europharm limited - tegaserodiin - Ärsyttävä suolen oireyhtymä - huumeet toiminnallisille ruoansulatuskanavan häiriöille - zelnorm on tarkoitettu toistuva oireenmukainen lyhytaikainen hoito naisilla, joilla on Ärtyvän suolen oireyhtymä (ibs), joiden pääasiallinen suolen tapa on ummetus, johon liittyy vatsan kipua/epämukavuutta tai turvotusta (ks. kohta 4.